Compare Stocks: PRLD, XNCR, BCAX, and MAZE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$24.66 -1.1%	$26.24	$10.30 ▼ $30.99	$1.63B	-0.75	604,357 shs	126,410 shs
MAZE Maze Therapeutics	$28.45 +1.8%	$27.88	$12.81 ▼ $53.65	$1.58B	2.22	657,978 shs	223,781 shs
PRLD Prelude Therapeutics	$5.68 +0.9%	$4.58	$0.85 ▼ $5.91	$453.18M	0.96	408,308 shs	111,217 shs
XNCR Xencor	$24.93 +7.8%	$17.03	$7.13 ▼ $25.09	$1.86B	0.85	853,122 shs	431,753 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	+2.72%	-10.06%	-10.16%	+24.51%	+114.26%
MAZE Maze Therapeutics	+2.83%	+2.46%	-0.60%	+14.27%	+107.04%
PRLD Prelude Therapeutics	+1.44%	+16.56%	+34.05%	+31.85%	+547.13%
XNCR Xencor	-0.94%	+7.14%	+32.34%	+122.09%	+201.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$24.66 -1.1%	$26.24	$10.30 ▼ $30.99	$1.63B	-0.75	604,357 shs	126,410 shs
MAZE Maze Therapeutics	$28.45 +1.8%	$27.88	$12.81 ▼ $53.65	$1.58B	2.22	657,978 shs	223,781 shs
PRLD Prelude Therapeutics	$5.68 +0.9%	$4.58	$0.85 ▼ $5.91	$453.18M	0.96	408,308 shs	111,217 shs
XNCR Xencor	$24.93 +7.8%	$17.03	$7.13 ▼ $25.09	$1.86B	0.85	853,122 shs	431,753 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	+2.72%	-10.06%	-10.16%	+24.51%	+114.26%
MAZE Maze Therapeutics	+2.83%	+2.46%	-0.60%	+14.27%	+107.04%
PRLD Prelude Therapeutics	+1.44%	+16.56%	+34.05%	+31.85%	+547.13%
XNCR Xencor	-0.94%	+7.14%	+32.34%	+122.09%	+201.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	2.71	Moderate Buy	$32.40	31.41% Upside
MAZE Maze Therapeutics	3.00	Buy	$66.00	131.97% Upside
PRLD Prelude Therapeutics	2.40	Hold	$7.67	34.98% Upside
XNCR Xencor	2.44	Hold	$24.86	-0.30% Downside

Current Analyst Ratings Breakdown

Latest PRLD, XNCR, BCAX, and MAZE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $33.00
8/12/2026	BCAX Bicara Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/12/2026	BCAX Bicara Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/12/2026	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$16.00 ➝ $23.00
8/12/2026	BCAX Bicara Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $39.00
8/12/2026	MAZE Maze Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
8/11/2026	BCAX Bicara Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$37.00 ➝ $39.00
8/6/2026	XNCR Xencor	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$19.00 ➝ $20.00
8/6/2026	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$26.00 ➝ $30.00
8/6/2026	XNCR Xencor	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$43.00 ➝ $44.00
7/30/2026	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$26.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.33 per share	N/A
MAZE Maze Therapeutics	$20M	79.02	N/A	N/A	$7.38 per share	3.86
PRLD Prelude Therapeutics	$22.42M	20.17	N/A	N/A	$1.09 per share	5.21
XNCR Xencor	$104.97M	17.66	N/A	N/A	$8.90 per share	2.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$137.95M	-$3.10	N/A	N/A	N/A	N/A	-41.49%	-38.59%	N/A
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	N/A
XNCR Xencor	-$91.92M	-$2.17	N/A	N/A	N/A	-155.59%	-28.66%	-20.38%	11/4/2026 (Estimated)

Latest PRLD, XNCR, BCAX, and MAZE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	-$0.82	-$0.0002	-$0.82	N/A	N/A
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
8/5/2026	Q2 2026	XNCR Xencor	-$0.8015	-$0.29	+$0.5115	-$0.29	$18.89 million	$51.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	11.59	11.59
MAZE Maze Therapeutics	0.09	18.31	18.31
PRLD Prelude Therapeutics	N/A	4.07	4.07
XNCR Xencor	N/A	6.39	6.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
MAZE Maze Therapeutics	N/A
PRLD Prelude Therapeutics	79.72%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	13.80%
MAZE Maze Therapeutics	5.30%
PRLD Prelude Therapeutics	49.20%
XNCR Xencor	5.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	66.17 million	57.04 million	N/A
MAZE Maze Therapeutics	121	55.55 million	52.61 million	N/A
PRLD Prelude Therapeutics	120	79.65 million	40.46 million	Optionable
XNCR Xencor	280	74.35 million	70.58 million	Optionable

PRLD, XNCR, BCAX, and MAZE Headlines

Recent News About These Companies

Xencor (NASDAQ:XNCR) Sets New 52-Week High - Should You Buy?

August 18 at 3:39 AM | marketbeat.com

Johnson & Johnson Purchases New Shares in Xencor, Inc. $XNCR

August 16 at 6:31 AM | marketbeat.com

Xencor, Inc. (XNCR) Stock Major Holders - Yahoo Finance

August 12, 2026 | finance.yahoo.com

Xencor (NASDAQ:XNCR) Hits New 1-Year High - Here's What Happened

August 12, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), Alpha Teknova (TKNO) and Solventum Corporation (SOLV)

August 11, 2026 | theglobeandmail.com

Xencor (NASDAQ:XNCR) Price Target Raised to $44.00

August 9, 2026 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Sets New 12-Month High on Strong Earnings

August 8, 2026 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Upgraded by Wall Street Zen to Hold Rating

August 8, 2026 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen

August 8, 2026 | marketbeat.com

Xencor: Q2 Earnings Snapshot

August 7, 2026 | sfgate.com

RBC Capital Sticks to Their Buy Rating for Xencor (XNCR)

August 7, 2026 | theglobeandmail.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Hold" by Brokerages

August 7, 2026 | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages

August 7, 2026 | marketbeat.com

Xencor Reports Second Quarter 2026 Financial Results

August 7, 2026 | aol.comA

Xencor (NASDAQ:XNCR) Price Target Raised to $30.00

August 6, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings

August 6, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Price Target Raised to $44.00 at Cantor Fitzgerald

August 6, 2026 | marketbeat.com

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates

August 5, 2026 | zacks.com

Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.51 EPS

August 5, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading Down 3.9% - Here's Why

August 3, 2026 | marketbeat.com

Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch

August 3, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD, XNCR, BCAX, and MAZE Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$24.66 -0.28 (-1.14%)

As of 01:40 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Maze Therapeutics NASDAQ:MAZE

$28.45 +0.50 (+1.80%)

As of 01:40 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Prelude Therapeutics NASDAQ:PRLD

$5.68 +0.05 (+0.89%)

As of 01:39 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Xencor NASDAQ:XNCR

$24.93 +1.81 (+7.83%)

As of 01:40 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRLD, XNCR, BCAX, and MAZE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRLD, XNCR, BCAX, and MAZE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRLD, XNCR, BCAX, and MAZE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD, XNCR, BCAX, and MAZE Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Maze Therapeutics NASDAQ:MAZE

Prelude Therapeutics NASDAQ:PRLD

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRLD, XNCR, BCAX, and MAZE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRLD, XNCR, BCAX, and MAZE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRLD, XNCR, BCAX, and MAZE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD, XNCR, BCAX, and MAZE Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Maze Therapeutics NASDAQ:MAZE

Prelude Therapeutics NASDAQ:PRLD

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools